JLPC(SH:600513)2022-04-27 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 404,359,214.35, representing a year-on-year increase of 21.79%[3] - The net profit attributable to shareholders for the same period was CNY 30,409,747.23, up 19.58% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 26,187,092.38, reflecting a 16.15% increase year-on-year[3] - The basic earnings per share for Q1 2022 was CNY 0.11, which is a 22.22% increase from the same period last year[3] - Operating profit for Q1 2022 was ¥44,448,638.51, up from ¥37,550,744.86 in Q1 2021, reflecting a growth of 18.8%[15] - Net profit for Q1 2022 was ¥37,482,656.87, compared to ¥31,943,156.96 in Q1 2021, representing an increase of 17.4%[15] - Basic and diluted earnings per share for Q1 2022 were both ¥0.11, up from ¥0.09 in Q1 2021[16] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 2,479,026,956.79, a 5.28% increase from the end of the previous year[3] - Total assets increased to ¥2,479,026,956.79 in Q1 2022 from ¥2,354,796,481.05 in Q1 2021, marking an increase of 5.3%[12] - Total liabilities rose to ¥1,155,889,188.49 in Q1 2022, up from ¥1,073,869,781.09 in Q1 2021, indicating an increase of 7.6%[12] - The equity attributable to shareholders at the end of Q1 2022 was CNY 1,188,841,159.41, up 2.65% from the previous year-end[3] Cash Flow - The net cash flow from operating activities was negative CNY 26,749,729.17, a significant decrease of 544.77% year-on-year due to increased purchases and pandemic-related cash collection issues[4] - Cash inflow from operating activities for Q1 2022 was $461,169,153.92, an increase of 19.1% compared to $387,158,666.49 in Q1 2021[18] - Net cash outflow from operating activities for Q1 2022 was -$26,749,729.17, a decline from a positive cash flow of $6,014,330.97 in Q1 2021[19] - Cash inflow from financing activities in Q1 2022 was $267,410,000.00, compared to $157,500,000.00 in Q1 2021, marking a 70% increase[19] - Net cash flow from financing activities for Q1 2022 was $61,378,082.86, up from $50,226,849.52 in Q1 2021, indicating a 22.7% increase[19] - Cash and cash equivalents at the end of Q1 2022 totaled $254,113,912.88, compared to $154,109,083.41 at the end of Q1 2021, representing a 64.8% increase[19] - Total cash outflow from investment activities in Q1 2022 was $103,280,313.10, a decrease from $131,402,567.01 in Q1 2021, showing a 21.4% reduction[19] Shareholder Information - The company had a total of 31,254 common shareholders at the end of the reporting period[6] - The largest shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd., held 37.75% of the shares[6] Research and Development - The company reported R&D expenses of ¥6,903,678.59 for Q1 2022, slightly up from ¥6,405,651.38 in Q1 2021[15] Future Plans - The company plans to expand its market presence and invest in new product development to drive future growth[17] Borrowing and Financing - The increase in short-term borrowings to ¥524,573,354.31 in Q1 2022 from ¥454,073,354.31 in Q1 2021 indicates a strategy to leverage financing for operational needs[12] Accounting Standards - The company did not apply the new accounting standards for the first quarter of 2022[20]